Afya initiated with a Neutral at UBS

UBS initiated coverage of Afya with a Neutral rating and $19.50 price target. The analyst believes revenue growth is the main source of debate for Afya. The firm estimates Afya can support above-average growth of 12% until 2028, but it believes the market is already pricing this into the shares. The estimates implied by the current share price fairly price in Afya’s revenue growth opportunities and execution risks, the analyst tells investors in a research note.